Paula Green Sells 1,101 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 1,101 shares of the company’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $37.65, for a total value of $41,452.65. Following the completion of the sale, the senior vice president now owns 129,380 shares in the company, valued at approximately $4,871,157. This represents a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Paula Green also recently made the following trade(s):

• On Wednesday, April 2nd, Paula Green sold 140 shares of Twist Bioscience stock. The stock was sold at an average price of $38.73, for a total value of $5,422.20.
• On Thursday, March 20th, Paula Green sold 291 shares of Twist Bioscience stock. The stock was sold at an average price of $41.68, for a total value of $12,128.88.
• On Thursday, March 6th, Paula Green sold 918 shares of Twist Bioscience stock. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38.

Twist Bioscience Price Performance

Twist Bioscience stock opened at $32.67 on Friday. Twist Bioscience Co. has a 1 year low of $31.56 and a 1 year high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96. The firm has a 50 day moving average price of $38.81 and a 200 day moving average price of $43.74. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -9.66 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The firm had revenue of $92.79 million for the quarter, compared to analyst estimates of $92.00 million. Sell-side analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

TWST has been the topic of several recent research reports. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. The Goldman Sachs Group dropped their price target on Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday. Guggenheim restated a “buy” rating and issued a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday. Robert W. Baird dropped their price objective on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday. Finally, Barclays reduced their target price on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a report on Thursday, April 10th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $50.40.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently modified their holdings of TWST. Barclays PLC increased its position in Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after purchasing an additional 104,420 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Twist Bioscience during the third quarter worth approximately $34,000. Franklin Resources Inc. increased its position in shares of Twist Bioscience by 3.4% in the third quarter. Franklin Resources Inc. now owns 252,064 shares of the company’s stock worth $11,756,000 after acquiring an additional 8,308 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Twist Bioscience by 67.5% in the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after acquiring an additional 82,953 shares during the period. Finally, Avanza Fonder AB acquired a new position in shares of Twist Bioscience during the 4th quarter valued at $1,059,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.